Central Nervous System

CNS remains among the most active and challenging realms of drug development, focused on significant and growing market opportunities in categories as diverse as Treatment-Resistant Depression and Alzheimer’s Disease. In 2021, we expect data readouts in novel areas such as psilocybin therapeutics and closely watched trials involving anti-amyloid, anti-tau and immune-modulatory therapeutics.

What we’re watching

  • 6 Alzheimer’s Disease (AD) trial readouts in 1H21
  • The FDA decision on potential approval for aducanumab for Alzheimer’s (1Q21)
  • Anti-Tau data
  • COMP360 / Psilocybin 2H21 data in Treatment-Resistant Depression (TRD)
  • April 3, 2021 PDUFA for ACAD’s pimavanserin in DRP
  • Ph2 POC data for SRPT’s Phase 2 Gene Therapy for DMD in 1Q21
  • Ph3 MDD WATERFALL Data for SAGE’s zuranolone in 1H21
Cowen Research Themes 2021

View the Handbook